Novavax, Inc. (NVAX)

Novavax is approaching its November 5 third-quarter earnings releasewith expectations for another quarterly loss and lower revenue. A Sanofi partnership milestone provides near-term financial support, while investors remain focused on whether recurring licensing income can offset declining product sales. NVAX is down 4.86% in the current regular sessionas of November 2, 2026.